Back to search results

Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients

Abroad (travel likely)Recruiting

Conditions

ALSFTD · ALS (Amyotrophic Lateral Sclerosis) · Frontal Temporal Dementia (FTD)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, Canada

    Contact: Study coordinator (Susan McCully, RN MN) · Susan.mccully@horizonnb.ca · (506) 471-9924
    Contact: Principal Investigator (Colleen O'Connell, MD, FRCPC)

  • Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada

    Contact: Study coordinator (Amélie Bujold, RN) · amelie.bujold.chum@ssss.gouv.qc.ca · 5148908000
    Contact: Study coordinator (Richard Miallot, PhD) · richard.miallot.chum@ssss.gouv.qc.ca · 5148908000
    Alex Parker, Ph.D. (Sub-investigator)
    Stephan Botez, MD, FRCPC (Sub-investigator)
    Contact: Principal Investigator (Genevieve Matte, MD)

  • University of Saskatchewan, Clinical Trials Support Unit, Saskatoon, Saskatchewan, Canada

    Contact: Study coordinator (Janet Peters, Clinical Research Coordinator, RN) · janet.peters@usak.ca · +1 639 317 5899
    Contact: Study coordinator (Joanne Boyer, RN) · joanne.boyer@usak.ca · +1 306 280 8001
    Contact: Principal Investigator (Kerri Schellenberg, MD, FRCPC)
    Ryan Verity, MD, FRCPC, CSCN (Sub-investigator)
Study leads

  • Genevieve Matte, MDCM, FRCP

    Principal Investigator

    CRCHUM

View source on ClinicalTrials.gov(opens in a new tab)